Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992131 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
A Phase 1 study, sponsored by pharmaand.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03992131 is a Phase 1 study that was terminated before completion, run by pharmaand. The registered enrollment target is 25 participants.
The verdict
NCT03992131, a Phase 1 study, was terminated before completion, sponsored by pharmaand.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in participants with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific participant populations in an expansion phase (Phase 2 cohorts).
Interventions
- DRUG Sacituzumab govitecan
- DRUG Rucaparib
- DRUG Lucitanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992131
The ClinicalTrials.gov registry entry for NCT03992131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sacituzumab govitecan is the first listed.
NCT03992131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03992131 about?
NCT03992131 is a clinical study titled "A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)". This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in participants with an advanced/metastatic solid malignancy (Phase 1b), followed by ...
What is the current status of trial NCT03992131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-06-28. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT03992131?
The interventions under investigation include: Sacituzumab govitecan (DRUG), Rucaparib (DRUG), Lucitanib (DRUG).
Who is sponsoring clinical trial NCT03992131?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.